Clinical Characteristics and Prognostic Analysis of Non‐ <i>NPM1‐ALK</i> Fusions in Pediatric Patients With ALK‐Positive Anaplastic Large‐Cell Lymphoma: A Single‐Center Retrospective Study in China

Pediatric ALK+ ALCL with non-NPM1-ALK fusions exhibits diverse clinical features and outcomes. TPM3-ALK fusions might correlate with a more favorable course, while other variants may face a potentially higher relapse risk. ALK inhibitors showed promising efficacy in the salvage setting. These preliminary findings highlight the need for larger prospective studies to validate mutation-specific risk stratification and therapeutic strategies.